TABLE 4.

Interleukin-2-based Studies Analyzing Predictors of Response and Survival

Study	No. of patients	Treatment	Predictors of response	Predictors of survival
Palmer 199214	327	HD IL-2, HD IL-2 plus LAK cells	NA	ECOG PS (0 vs 1), DTI (>24 mo or <24 mo), no. of disease sites (1 vs >2)
Royal 199615	239	HD IL-2, PEG IL-2, HD IL-2 plus LAK cells	Prior nephrectomy, no prior immunotherapy, lower platelet nadir, higher rebound lymphocytosis	NA
Fyfe 199512	255	HD IL-2 alone	ECOG PS 0	ECOG PS 0, prior nephrectomy, DTI
Rosenberg 199813	227	HD IL-2 alone	No prior immunotherapy, total amount of IL-2 (1st course), higher rebound lymphocytosis	NA
Yang 200311	156	HD IL-2 alone, LD IL-2, subcutaneous IL-2	Absence of local recurrence, higher baseline weight, corrected calcium, greater no. of doses	Lower baseline platelet count, disease confined to lungs, response to IL-2
Upton 200522	231	HD IL-2 alone, HD IL-2 plus IFN, LD IL-2 plus IFN or 5-flourouracil	Clear cell tumors, no papillary features, alveolar features >50%, no granular features	NA
Atkins 200523	66	HD IL-2 alone, LD IL-2	High CAIX	High CAIX
Current study	259	HD IL-2 alone	Better MSKCC score, higher baseline weight, no prior immunotherapy	Higher baseline albumin, fewer disease sites, response, lower peak TSH, lower ECOG PS, higher rebound lymphocytosis, lower platelet nadir

HD indicates high-dose; IL-2, interleukin-2; LAK, lymphokine-activated killer; NA, not available; ECOG PS, Eastern Cooperative Oncology Group performance status; DTI, diagnosis to treatment interval; PEG, polyethylene glycol; LD, low-dose; IFN, interferon-α; CAIX, carbonic anhydrase inhibitor; MSKCC, Memorial Sloan-Kettering Cancer Center; TSH, thyroid-stimulating hormone.